RxDoctor Payments Data

Paul Grandinetti, MD

Internal Medicine · Reynoldsburg, OHNPI 1972588689

Payments from drug & device makers

$4,779in general payments, 2019–2025

Across 306 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$633
  • Novo Nordisk$539
  • AbbVie$380
  • Pfizer$318
  • Lilly USA, LLC$283
  • Boehringer Ingelheim$255
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,74999%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,779 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$101,579
Medicare patients
141
Services billed
3,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$97,502
EliquisApixaban68$88,015
JardianceEmpagliflozin48$58,318
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$48,617
XareltoRivaroxaban29$37,800
JanuviaSitagliptin Phosphate33$32,502
Tresiba Flextouch U-200Insulin Degludec27$22,991
FarxigaDapagliflozin Propanediol13$21,284
MounjaroTirzepatide19$19,226
Breo ElliptaFluticasone/Vilanterol25$17,383
LinzessLinaclotide13$12,005
ShingrixVaricella-Zoster Ge/As01b/Pf37$8,727
Atorvastatin Calcium420$5,524
Rosuvastatin Calcium185$4,890
AbrysvoRsv Vacc, Pref A And Pref B/Pf13$4,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$539$97,50281 claims
PfizerEliquis, Abrysvo$318$92,19381 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$244$74,726117 claims
Boehringer IngelheimJardiance$255$58,31848 claims
Johnson & JohnsonXarelto$138$37,80029 claims
MerckJanuvia$245$32,50233 claims
AstraZenecaFarxiga$633$21,28413 claims
Lilly USA, LLCMounjaro$283$19,22619 claims
AbbVieLinzess, Synthroid$380$13,49939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Reynoldsburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →